| INTRODUCTION
Fetal lower urinary tract obstruction (LUTO) is a rare congenital anomaly that occurs in 2 to 3 cases per 10 000 births as a consequence of an obstruction of the fetal bladder outlet (urethra). As a consequence, fetuses diagnosed with LUTO develop oligohydramnios or anhydramnios that causes pulmonary hypoplasia, the main cause of early neonatal mortality and morbidity (Potters' sequence). In addition, infants with prenatal diagnosis of severe LUTO are at increased risk to progress to end stage renal disease after birth. The ultrasound diagnosis of LUTO is feasible as these fetuses present with megacystis, in combination with a variable degree of hydro-ureteronephrosis and oligohydramnion. 1 Because of the severity of the condition, fetal surgery has been proposed for this situation several decades ago. There are different fetal surgical options of which vesicoamniotic shunting (VAS) has by far been best studied. The main objective of fetal intervention for LUTO is to prevent severe pulmonary hypoplasia and end stage renal disease by resolving or bypassing the obstruction.
There is much debate in the fetal therapy community on the value of VAS in the treatment of LUTO, mainly relating to difficulties in selecting the fetuses that may benefit most from this intervention. 2 Therefore, the question that was debated during the 2017 International Society for Prenatal Diagnosis (ISPD) meeting in San Diego, California, was whether all prenatally detected fetuses with LUTOs should be shunted or not. 
| BACKGROUND
While supportive of this debate statement, it is important to emphasize that an informed consent process should be available to the patient diagnosed with a fetus with a LUTO. Evidence-based information is required to inform, educate, counsel, and support a decision related to the risk/benefit status of the prenatal situation for both mother and fetus. 3, 4 To achieve this, firstly a clear classification and definition for LUTO anomalies in the male fetus is required (Table 1) .
Lower urinary tract obstruction (LUTO) and male gender are both required for the fetus to be a urinary-amniotic fluid shunt candidate. LUTO is not a diagnosis but is a prenatally detected ultrasound identified "sign. 
| EVIDENCE FOR THE FETAL USE OF VESICO-AMNIOTIC SHUNTING (VAS)
The PLUTO trial (Percutaneous shunting in lower urinary tract obstruction) was an unsuccessful randomized clinical trial (RCT) that was closed earlier due to enrollment issues. The RCT had expected to compare the fetal VAS "obstructive by-pass" treatment compared with the conservative (no shunting) management. The conclusion of the study was that survival seemed to be higher in the VAS fetuses, but the size and direction of the effect remained uncertain such that benefit could not be conclusively proven. 
| OTHER STAGING AND EVALUATIVE METHODS/OPTIONS FOR BETTER VAS SELECTION AND TREATMENT
Ruano et al (2016a) has proposed a staging classification for LUTO in an attempt to better classify this disease and select cases for prenatal treatment (Table 3) . 9 The same group has described an in-utero observation and calculation of the % of bladder refilling 48 hours after the first vesicocentesis to reliably predict intra-uterine renal failure. 10 At the same time, shunt modifications for VAS treatment are under investigation that include a pressure limited/regulated system to allow for possible bladder cycling (filling and emptying) in order to mimic "normal" bladder function. Lamb models using low and high pressure engineered shunts have indicated that low pressure VAS prevents multi-cystic dysplastic kidney damage in the surgically created urinary obstruction scenario. 11 
| OTHER PROPOSED ETHICAL TREATMENT OUTCOMES FOR LUTO AND VAS
In the decision to proceed to VAS or not, other ethical outcomes such as decreased or minimized neonatal musculo-skeletal or pulmonary morbidity due to severe oligohydramnios should be considered following clear informed consent.
1 What's already known about this topic?
• LUTO is a rare but life-threatening condition affecting the fetus and child in which prenatal therapy is currently being offered but remains controversial. A recent RCT comparing this treatment to post-natal treatment in selected cases failed to come to robust conclusions due to under-recruitment. So, the controversy persists.
What does this study add?
• Fetal cystoscopy is the only method that can objectively diagnose the cause of LUTO prenatally. 15 This may be the reason that recent observations suggest that fetal cystoscopy is associated with a higher chance of having adequate renal function at 2 years of age when compared with a group of children that underwent prenatal shunting. 16 Although this was not a randomized trial, the fact that fetal cystoscopy was used a diagnostic tool to select good candidates for fetal therapy (only fetuses identified with PUV were treated, while fetuses with urethral atresia opted for termination of pregnancy or
were not treated prenatally) may have contributed to the better outcome in these cases. 16 
| Urethral obstructions can present with variable severity
It is well known that LUTO is associated with a large spectrum of clin- Recently, we proposed a prenatal classification of LUTO according to the specific fetal renal condition. 6, 7 This classification is detailed in Table 3 . Based on detailed clinical prenatal evaluation, one can distin- and 70%, respectively, after fetal intervention.
• Stage III represents the most severe form of LUTO with abnormal renal function already present. 
| CONCLUSIONS OF THE MODERATOR
The points of view of the debaters defended in the above sections do not differ fundamentally. It is clear that a lot of the controversy in the prenatal treatment of LUTO is related to the fact that treatment has been applied to fetuses with very different etiologies, pathophysiologies, severities, and using different techniques. The proposed classification 16 could potentially create uniformity in the selection of cases that could benefit most from the procedure and create a framework for retrospective and prospective evaluation of treated cases. However, in order to be clinically and scientifically useful, the classification requires refinement of the definitions of "echogenicity," "unfavorable 
